TNFSF10 and acute coronary syndrome: IL-18, also shown to be elevated in acute coronary syndromes [9,14], can suppress TRAIL gene expression and contribute to the reduced TRAIL levels observed in patients with advanced CAD [7], linking TRAIL to inflammasome activation and suggesting that the ratio of IL-18 to TRAIL may be an important predictive marker.